1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Cardiomegaly in 16 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent evidence indicates that the GTPase activated Rho/Rho-kinase pathway contributes angiotensin II-induced cardiac hypertrophy and vascular remodeling." | 7.73 | Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. ( Choy, DF; da Cunha, V; Dole, WP; Halks-Miller, M; Johns, A; Li, W; Light, DR; Mahmoudi, M; Martin-McNulty, B; Schroeder, M; Vincelette, J; Wang, YX, 2005) |
| "In this study, the role of the RhoA/Rho-kinase (RhoA/ROCK)-signaling pathway in cardiovascular dysfunction associated with hyperthyroidism was examined with the use of fasudil, a Rho-kinase inhibitor." | 3.78 | RhoA/ROCK may involve in cardiac hypertrophy induced by experimental hyperthyroidism. ( Jianping, Z; Li, C; Na, W; Peng, G; Shengjiang, G; Yanzhong, C, 2012) |
| "Recent evidence indicates that the GTPase activated Rho/Rho-kinase pathway contributes angiotensin II-induced cardiac hypertrophy and vascular remodeling." | 3.73 | Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. ( Choy, DF; da Cunha, V; Dole, WP; Halks-Miller, M; Johns, A; Li, W; Light, DR; Mahmoudi, M; Martin-McNulty, B; Schroeder, M; Vincelette, J; Wang, YX, 2005) |
| "The present study was undertaken to investigate the effect of fasudil, a specific Rho-kinase inhibitor, in pathological cardiac hypertrophy induced by partial abdominal aortic constriction (PAAC) for 4 weeks in comparison with physiological cardiac hypertrophy caused by chronic swimming training (CST) for 8 weeks in rats." | 3.73 | Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. ( Balakumar, P; Singh, M, 2006) |
| "Endothelin-1 (ET-1) induces cardiac hypertrophy." | 3.70 | Ca2+/calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy. ( Aikawa, R; Hayashi, D; Komuro, I; Kudoh, S; Mizukami, M; Nagai, R; Shibasaki, F; Shiojima, I; Toko, H; Yazaki, Y; Zhu, W; Zou, Y, 2000) |
| "Hypertensive cardiac hypertrophy is associated with reduced coronary flow reserve, but its impact on coronary flow regulation and vasomotor function remains incompletely understood and requires further investigation." | 1.46 | Enhanced endothelin-1/Rho-kinase signalling and coronary microvascular dysfunction in hypertensive myocardial hypertrophy. ( Hein, TW; Kuo, L; Lu, G; Ren, Y; Tsai, SH; Xu, X, 2017) |
| "Pathologic cardiac hypertrophy is one of the leading causes of sudden death from cardiac disease and involves a complex network of bio-signaling mechanisms." | 1.42 | N-[(11)C]-methyl-hydroxyfasudil is a potential biomarker of cardiac hypertrophy. ( DaSilva, JN; Fernando, P; Moreau, S; Valdivia, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsai, SH | 1 |
| Lu, G | 1 |
| Xu, X | 2 |
| Ren, Y | 1 |
| Hein, TW | 1 |
| Kuo, L | 1 |
| Zhuang, R | 1 |
| Wu, J | 1 |
| Lin, F | 1 |
| Han, L | 1 |
| Liang, X | 1 |
| Meng, Q | 1 |
| Jiang, Y | 1 |
| Wang, Z | 1 |
| Yue, A | 1 |
| Gu, Y | 1 |
| Fan, H | 1 |
| Zhou, X | 1 |
| Liu, Z | 1 |
| Ocaranza, MP | 1 |
| Fierro, C | 1 |
| Jalil, JE | 1 |
| Moya, J | 1 |
| Gonzalez, L | 1 |
| Molina, C | 1 |
| Mancilla, C | 1 |
| Yan, X | 1 |
| Jiao, K | 1 |
| Song, X | 1 |
| Moreau, S | 1 |
| DaSilva, JN | 1 |
| Valdivia, A | 1 |
| Fernando, P | 1 |
| Ying, Z | 1 |
| Yue, P | 1 |
| Zhong, M | 1 |
| Sun, Q | 1 |
| Mikolaj, M | 1 |
| Wang, A | 1 |
| Brook, RD | 1 |
| Chen, LC | 1 |
| Rajagopalan, S | 1 |
| Na, W | 1 |
| Peng, G | 1 |
| Jianping, Z | 1 |
| Yanzhong, C | 1 |
| Shengjiang, G | 1 |
| Li, C | 1 |
| Ho, TJ | 1 |
| Huang, CC | 1 |
| Huang, CY | 1 |
| Lin, WT | 1 |
| Satoh, S | 1 |
| Kawasaki, K | 1 |
| Ikegaki, I | 1 |
| Asano, T | 1 |
| Shimokawa, H | 2 |
| Zhang, ZJ | 1 |
| Fan, YF | 1 |
| Zhang, ZY | 1 |
| Xie, PY | 1 |
| Fang, HC | 1 |
| Su, YS | 1 |
| Higashi, M | 1 |
| Hattori, T | 1 |
| Hiroki, J | 1 |
| Mukai, Y | 1 |
| Morikawa, K | 1 |
| Ichiki, T | 1 |
| Takahashi, S | 1 |
| Takeshita, A | 1 |
| Wang, YX | 1 |
| da Cunha, V | 1 |
| Martin-McNulty, B | 1 |
| Vincelette, J | 1 |
| Li, W | 1 |
| Choy, DF | 1 |
| Halks-Miller, M | 1 |
| Mahmoudi, M | 1 |
| Schroeder, M | 1 |
| Johns, A | 1 |
| Light, DR | 1 |
| Dole, WP | 1 |
| Balakumar, P | 1 |
| Singh, M | 1 |
| McKinsey, TA | 1 |
| Kass, DA | 1 |
| Murata, M | 1 |
| Fukuda, K | 1 |
| Ishida, H | 1 |
| Miyoshi, S | 1 |
| Koura, T | 1 |
| Kodama, H | 1 |
| Nakazawa, HK | 1 |
| Ogawa, S | 1 |
| Zhu, W | 1 |
| Zou, Y | 1 |
| Shiojima, I | 1 |
| Kudoh, S | 1 |
| Aikawa, R | 1 |
| Hayashi, D | 1 |
| Mizukami, M | 1 |
| Toko, H | 1 |
| Shibasaki, F | 1 |
| Yazaki, Y | 1 |
| Nagai, R | 1 |
| Komuro, I | 1 |
1 review available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cardiomegaly
| Article | Year |
|---|---|
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiomegaly; Cardiovascular Agents; | 2007 |
15 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cardiomegaly
| Article | Year |
|---|---|
Enhanced endothelin-1/Rho-kinase signalling and coronary microvascular dysfunction in hypertensive myocardial hypertrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Cardiomegaly; Endothelin-1; Endo | 2017 |
Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of end‑stage pulmonary hypertension with left heart disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomegaly; Cell Line; Heart Diseases; Hum | 2018 |
Rho kinase activation in circulating leukocytes is related to hypertensive myocardial remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Atrial Remodeling; Blood Pressure; Cardiomeg | 2018 |
Shen'ge powder decreases the cardiomyocyte hypertrophy in chronic heart failure by activating the Rho protein/Rho-associated coiledcoil forming protein kinase signaling pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Cardiomegaly; Cell Survival; Dise | 2019 |
N-[(11)C]-methyl-hydroxyfasudil is a potential biomarker of cardiac hypertrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Biomarkers; Cardiomegaly; Cell Nucleus; Cell | 2015 |
Air pollution and cardiac remodeling: a role for RhoA/Rho-kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Atmosphere Exposure Chambers | 2009 |
RhoA/ROCK may involve in cardiac hypertrophy induced by experimental hyperthyroidism.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; bcl-2-Associated X Protein; Cardi | 2012 |
Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bi | 2012 |
Evidence of a direct cellular protective effect of Rho-kinase inhibitors on endothelin-induced cardiac myocyte hypertrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomegaly; Cells, Cultured; Cytoprotectio | 2012 |
[Effects of rho-kinase inhibitor on cardiac hypertrophy of left ventricle in spontaneously hypertensive rats].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomegaly; Heart Ventricles; Male; Nifedi | 2012 |
Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Aorta, Thoracic; Cardiomegal | 2003 |
Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Apolipoproteins E; Atrial Na | 2005 |
Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adaptation, Physiological; Animals; Blood Pressure; C | 2006 |
Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, enhances L-type Ca2+ current and [Ca2+]i transient in cardiomyocytes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium; Calcium-Calmodulin-Dependent Protei | 1999 |
Ca2+/calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Animals, Newborn; Calcimycin; Calcineurin; C | 2000 |